Webinar: Shining a brighter light on drug discovery: Converting endpoint microplate assays to real-time data output by LabX Media Group

Host Login

About This Webinar

Microplate readers are the workhorses of early stage drug discovery. However, they are often used only for endpoint assays. While automation can force large numbers of samples through these workflows, this approach is problematic for discovery-based applications where the timing and duration of effects are unknown.

This webinar sponsored by BMG LABTECH will explore how advanced plate readers and assay technologies move beyond high-throughput endpoint studies to enable continuous monitoring of metabolic activity dynamics, transcriptional regulation, foreign gene expression, and cellular health. By expressing a synthetic luciferase that does not require external excitation, researchers can induce cellular targets to continuously modulate their bioluminescent signals. With atmospheric control and flexible programming, modern microplate readers can quickly and inexpensively obtain more data earlier in the pipeline.

Presenters

Dan Close, PhD

Chief Scientific Officer of 490 BioTech

Dan Close is the chief scientific officer of 490 BioTech, a biotechnology company focused on developing autonomously bioluminescent assay solutions that function without luciferin treatment to continuously provide real-time data output. Dr. Close obtained his doctorate degree in Genome Science and Technology from The University of Tennessee before serving as a post-doctoral research associate for the Joint Institute for Biological Sciences at Oak Ridge National Laboratory. Following his postdoctoral assignment, Dr. Close was selected as a Eugene P. Wigner Fellow by the Department of Energy, where he leveraged his synthetic genetic pathway design experience to develop hydrocarbon biofuel production pathways in industrially relevant organisms. In 2018, he left this position to serve as the chief scientific officer of 490 BioTech.

Mark Wienhold

Lead Scientist for Cellular Technologies

Mark Wienhold is the lead scientist for cellular technologies at 490 BioTech. Dr. Wienhold obtained his graduate degree in Cellular and Developmental Biology from the University of Connecticut, where his work focused on stem cell biology. His strong cell and molecular biology background lead him to the University of Wisconsin-Madison, where he applied this experience towards mammalian cell developmental biology, and then to the University of Tennessee, where he specialized in developing customized genetic modification tools for non-model systems. Dr. Wienhold joined 490 BioTech in 2019 to head cellular development.

Carl Peters, PhD

Senior Application Specialist

Carl Peters is a Microplate Reader Senior Application Scientist at BMG LABTECH. He obtained a PhD in Cell and Molecular Biology from Northwestern University while studying Protein Kinase C signaling. Prior to joining BMG LABTECH, he was an adjunct professor of Biology at Roosevelt University and subsequently a Clinical Assistant Professor in the School of Molecular Biosciences at Washington State University.